键凯科技 (688356.SH) Latest Company News

Aug 25, 2026, 08:16 UTC
Jiankai Technology announced the termination of its wholly-owned subsidiary Tianjin Jiankai's phase III clinical study of polyethylene glycol irinotecan (JK1201I) for relapsed or progressive extensive-stage small cell lung cancer, and will fully impair the capitalized R&D amount of 70.6411 million yuan, reducing its 2026 half-year total profit by the same amount.
Source:
- finance.sina.cn
Aug 24, 2026, 08:36 UTC
Wu Kaiting, a shareholder holding more than 5% of Jiankai Technology, completed a reduction of 3% of the company's shares through centralized bidding and block trades between July 15 and August 24, 2026.
Source:
- finance.sina.cn

688356.SH